Intravenous Magnesium in Patients with Malignant Mesothelioma Receiving Cisplatin during Surgery

Inclusion Criteria

• Adults with malignant mesothelioma admitted for hyperthermic intraoperative chemotherapy with cisplatin (HIOCC)
• Glomerular filtration rate (GFR) >= 30 ml/min/1.73 m^2 at the time of enrollment
• Patients must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Patients with a pre-treatment serum magnesium level > 2.5 mg/dl or < 1.3 mg/dl at the preoperative visit
• Patients with acute kidney injury (AKI) at the time of enrollment, assessed by Kidney Disease Improving Outcomes Criteria (serum creatinine increase >= 1.5 x baseline)
• Patients with estimated glomerular filtration rate < 30 ml/min/1.73 m^2 at the time of enrollment
• Patients with neuromuscular disease (e.g., amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, myositis)
• Patients with sustained bradycardia (heart rate < 50 beats per minute on 1 or more electrocardiograms [EKGs] in the preceding 90 days) or 2nd degree atrioventricular (AV) heart block type 2 or higher with the absence of a functioning pacemaker
• Participants who are receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to intravenous magnesium
• Participants with uncontrolled intercurrent illness
• Participants with psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because they may need magnesium for treatment of preeclampsia or eclampsia, apart from this study